Top 10 embor.embopress.org Competitors

bioxbio.com

journal impact search engine. bioxbio.com includes the journal factors, issn, number of articles and other detailed information of over 11000 journals in different fields.

lncrnablog.com

anavar for sale in usa, purchase anavar pills online fast worldwide shipping. anavar 50 for sale, buy oxandrolone tablets online, oral steroids worldwide sequre shipping.

pdbj.org

pdbj maintains the single global pdb/bmrb/emdb archives of macromolecular structures and provides integrated tools for searching & analyzing pdb data

genesdev.cshlp.org

a biweekly scientific journal publishing high-quality research in molecular biology and genetics, cancer biology, biochemistry, and related fields

biologicalexceptions.blogspot.com

Biology Concepts – pollen, plastid inheritance, gymnosperms, angiosperms I am coming to believe that plants are more complex than anima...

gideononline.com

Epidemiologists can now get data insights faster with the Quantify tool - one of the most cutting-edge additions to the GIDEON database.

scienceopen.com

Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 mont

ajpheart.physiology.org

the american physiological society publishes journals and books in many disciplines within physiology. the society’s 15 distinguished scientific journals are dedicated to the advancement of physiological research, which has formed the basis for many biomedical advances